Sanofi and Regeneron’s Dupixent shows positive results in phase 3 trial

A phase 3 trial assessing the investigational use of Sanofi and Regeneron’s Dupixent – also known as dupilumab – in children aged one to 11 years with eosinophilic oesophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens.